This article looks at how theory could be put into practice suggesting ways to implement a differential pricing system for branded medicines in the EU that can enhance overall welfare.
This post provides an overview of Dr Irene Papanicolas and Professor Alistair McGuire’s OHE Lunchtime Seminar on the effect of financial incentives on hip replacement in England.
Articles co-authored by Adrian Towse, Martina Garau, Donna Messner, and Penny Mohr exploring future expectations of drug relative effectiveness in Europe and comparative effectiveness in the USA just published online.
The business model for antibiotics is broken. We looked at other industries facing conceptually similar challenges - particularly when the incentive for R&D is delinked from the volume of sales.
Just published in Health Economics is an article by OHE’s Adrian Towse and others on pharmaceutical pricing in middle and low income countries (MLICs).
Dr. Aslam Anis, Director of the Centre for Health Evaluation and Outcomes Sciences (CHEOS) in Canada will undertake a short sabbatical with the Office of Health Economics in February 2015.
OHE Lunchtime Seminar with Professor Aslam H. Anis, University of British Columbia, Vancouver's Centre for Health Evaluation and Outcome Sciences and the CIHR Canadian HIV Trials Network.
